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ABSTRACT 
Several studies have reported decreased platelet 5-HT uptake in patients of major 
depression. The present study was undertaken with the aim to study the active platelet 5-HT 
uptake in depressed patients and effect of treatment with imipramine/ECT on platelet 5-HT uptake 
in these patients. 30 patients of major depression and equal number of age and sex-matched 
controls were included in the study. The depressives received imipramine (N=15) or ECT (N=15). 
Pretreatment active platelet 5-HT uptake was lower in depressives. Treatment with imipramine 
resulted in significant decrease in 5-HT uptake while with ECT there was significant increase. The 
serotonergic mechanisms are discussed. 
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Considerable evidence has accrued in 
the last two decades to support the hypothesis 
that alterations in serotonergic neuronal 
function in the central nervous system occur in 
patients with major depression (Owens & 
Nemeroff, 1994). These findings include : (a) 
reduced CSF concentrations of 5-HIAA, the ma-
jor metabolite of serotonin, in drug -free 
depressed patients, (b) reduced concentrations 
of 5-HT and 5-HIAA in postmortem brain tissue 
of depressed and (or) suicidal patients, (c) 
decreased plasma tryptophan concentrations 
in depressed patients, (d) in general, all 
clinically efficacious antidepressants augment 
5-HT neurotransmission following chronic 
treatment, (e) clinically efficacious 
antidepressant action by all inhibitors of 5-HT 
uptake (f) increases in the density of 5HT2 bind-
ing sites in postmortem brain tissue of de-
pressed patients and suicide victims as well as 
in platelets of 5-HT transporter (determined with 
3H imipramine) sites in platelets of 
drug-free depressed patient^. 
Numerous studies have shown a low 
number of
 3H imipramine binding sites (Bmax) 
in platelets of major depression (Briley et al., 
1980; Asarch et al., 1980; Paul et al., 1981; 
Tnyetal., 1994; Gronieretal., 1994; Lawrence 
et al., 1993). Although it has been suggested 
that decreased platelet imipramine binding may 
be a putative biological marker of depressive 
illness, some studies have not confirmed this 
finding. Ellis & Salmond (1973) performed a 
meta analysis of published reports on 
imipramine binding in groups of depressed and 
healthy control subjects and found that there 
was a highly significant decrease in (Bmax) 
maximal binding values in the depressed 
subjects. This finding remained highly 
significant even when only high affinity 
binding studies (Kd<1 nmo1/L) were 
considered, although the absolute size of this 
decrease was smaller. 
The mechanism of antidepressant action 
of electroconvulsive therapy (ECT) is still a 
matter of controversy. Shapira et al (1992) 
showed that ECT enhances central serotoner-
gic responsivity. Subramanyam (1975) reported 
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that ECT produced a sustained increase in the 
synthesis and turn over of amines in the brain. 
Jori et al. (1975) reported that ECT caused sig-
nificant increase in CSF 5-HIAA at the time of 
recovery than at the beginning of the treatment. 
Costain et al. (1979) reported that ECT potenti-
ates 5-HT effects in test animals (rats). 
The present study was undertaken with 
the aim to study active platelet 5-HT uptake in 
depressed patients and effect of imipramine and 
ECT on active platelet 5-HT uptake in these 
patients. 
MATERIAL AND METHOD 
Subjects for the study consisted of a 
depressive group and a control group. All 
consecutive drug-naive patients of depression 
of both sexes between 17-60 years of age who 
were admitted in the department of psychiatry, 
K.G.'s Medical College. Lucknow were 
screened. DSM-III-R criteria (APA, 1987) was 
used for diagnosis of major depression-single 
episode or recurrent. Hamilton Rating Scale for 
Depression (Hamilton, 1960) (HRSD) was used 
to rate the severity of depression and those 
patients scoring 17 points or more on 17 item 
scale were included in the study. Exclusion 
criteria were presence of physical illness 
requiring active medication, papilledema, 
epilepsy, mental retardation, organic brain 
syndrome, pregnancy, and drug/alcohol 
dependence (Dalai, 1997). 
Control group comprised of normal 
healthy volunteers matched for age and sex with 
depressives. Controls were screened on 
Cornell Medical Index (CMI) (Broadman et al., 
1949) and those who gave thirty or more "yes" 
responses on entire CMI and/orten or more 'yes' 
responses on M-R sections of CMI were ex-
cluded. Controls with past or family history of 
depression were also excluded. Other 
exclusion criteria were same as for the 
depressive group. 
All the subjects included in the study were 
kept drug free for seven days except tablet 
lorazepam on s.o.s. basis because antidepres-
sants or antipsychotics may alter platelet 5-HT 
uptake (Todrick & Tait, 1969; Boullin et al., 
1976). The subjects were kept on a diet free of 
pineapples, bananas, plums and nuts for the 
entire duration of study Controls were also kept 
on a similar dietary restriction for a period of 7 
days before taking blood sample This specific 
restriction on the diet was imposed especially 
for tryptophan containing food items as tryp-
tophan a precursor of 5- hyd
roxytryptamine (5-
HT), can alter the levels of 5-HT and its me-
tabolites in serum and CSF (Wurtman & 
Fernstrom, 1974; Sneddon, 1973; Knott & 
Curson, 1972) and ois may alter the results. 
The depressives were divided randomly 
into imipramine group (N=15) and ECT group 
(N=15) Subjects in the imipramine group 
received tablet imipramine on a fixed dosage 
of 225 mg/day i.e. 75 mg three times daily which 
was achieved within a week starting from 75 
mg/day on first three days followed by 150 mg/ 
day on next three days and 225 mg/day there-
after, which was continued till the end of 5 weeks 
study period provided there were no serious 
side-affects of imipramine which were assessed 
on Asberg side effect scale which was adminis-
tered at weekly interval. The treatment was 
stopped at any assessment point at which clini-
cal improvement occurred i.e. HRSD score fell 
below 5 points. 
Subjects in the ECT group were given 
only modified electroconvulsive therapy first 
three on alternate days and on every fourth day 
thereafter to a maximum of ten at the end of 
five weeks treatment phase. Atropine (1 mg IV.) 
was administered two minutes before the 
anaesthetic medication. Thiopental (2-3 mg/kg 
body weight I.V.) was used as the anaesthetic 
agent and succinylcholine (0.5-1 0 mg/kg body 
weight I.V.) as muscle relaxant. Sine wave ECT 
was administered by "Electrocon" modei 
manufactured by Associated Electronic 
Engineers Bangalore usmg bitemporal 
electrodes. 90 to 120 volt electrical stimulus for 
0.5-1.0 seconds was given to induce seizures. 
Severity of depression and response to 
imipramine/ECT was assessed on HRSD which 
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was administered on the day of nospitalization 
and then at weekly interval till the end of the 
treatment phase. 
Routine haemogram, SGOT, serum 
bilirubin, serum creatinine, serum proteins, 
blood urea, blood sugar, urine examination and 
biteteral fundus oculi examination were done 
in all subjects and those with abnormal test 
results were excluded. For platelet 5-HT uptake 
estimation, subjects were kept overnight 
fasting and in the morning (between 8 to 9 a.m.) 
10 ml venous blood was taken by disposable 
syringe rinsed with 3.8% sodium citrate and 
transferred into polypropylene tube containing 
1 ml of 3.8% sodium citrate as anticoagulant 
(Mills & Robert, 1967). Blood samples were 
drawn in fasting condition in the morning (Melt-
zer et al., 1981) to control for the diurnal rhythm 
of platelet 5-HT uptake The sample tubes were 
immediately (within one hour) sent to Indus-
trial Toxicology Research Centre, Lucknow for 
assessment. 
The platelet 5-HT uptake was estimated 
by following the principles of the method 
described by Scott et al. (1979). The counting 
was done in a liquid scintillation counter (LKB 
Wallac). In order to assess the active uptake, 
the passive uptake was subtracted from the 
total uptake. The data is represented in terms 
of picomoles of
 3H (tntiated) 5-HT uptaken / 
108 piatelet/5 minutes. 
For depressives the platelet 5-HT uptake 
estimation was done prior to starting the 
treatment and at the end of treatment. For 
controls only one sample was estimated. 
Student's "t" test was used to find the 
level of significance between two mean values. 
Paired T test was used to determine the level 
of significance of mean of difference where the 
observation were paired. 
RESULTS 
The sample for the study consisted of 30 
patients of major depression and equal number 
of age and sex-m3tched controls Mean age of 
depressives and controls was 43.93 and 42.60 
years respectively and there was no significant 
difference between the two. 
HRSD scores in depressives receiving 
imipramine was 28.26±3.94 which decreased 
significantly to 5.0±4.23 after treatment. HRSD 
scores in depressives receiving ECT's was 
28.47±4.41 which decreased significantly to 
5.07±4.23 after treatment. 
TABLE 
COMPARISON OF ACTIVE PLATELET 6-HT UPTAKE* 
IN DEPRESSIVES AND CONTROLS 
Imipramine Group ECT Group Controls 
(N=15) (N=15) (N=30) 
A B C 
Pre-treatment 1.27±0 43 1.32±0.40 1.795*0.45 
D E 
Post-treatment 0.28±0.19 1.97±0.38 
•Uptake'values in picomoles of
 3H 5-HT uptaken/10
8 
platelets/5min 
AvsC t=3.66; df=43; p<001 
BvsC t=3.38; df=43, p<01 
AvsD t=7.52; df=14; p<01 
BvsE t=3.87; df=14, p<01 
Pretreatment active platelet 5-HT 
uptake in depressives in imipramine group was 
1.27±0.43 (pmol/10
8 platelets/5min) and 
1.32±0.40 in ECT group which were signifi-
cantly lower as compared to controls 
(1.795±0.45). There was no significant 
correlation between active platelet 5-HT uptake 
and severity of depression. There was also no 
significant correlation between active platelet 
5-HT uptake between the subjects with first 
episode depression and recurrent depression. 
After treatment with imipramine, there 
was a significant decrease in active platelet 
5-HT uptake (0.28±0.19) from pretreatment 
levels. Mean percentage blocking (decrease) 
in active platelet 5-HT uptake after treatment 
with imipramine was 76.47±16.87. 
After treatment with ECT, there was a 
significant increase in active platelet 5-HT 
uptake (1 97±0.38) from pretreatment levels. 
Mean number of ECTs given to depressives was 
8.87±2.45. Percentage increase in active 
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platelet 5-HT uptake after, ECTs was 
47.06±34.71. 
DISCUSSION 
This study was undertaken with the aim 
to study the active platelet 5-HT uptake in 
depressed patients and the effect of imipramine 
and ECT on active platelet 5-HT uptake in these 
patients The major finding of our study was 
that platelet 5-HT uptake was lower in patients 
of major depression as compared to controls 
and imipramine treatment resulted in further 
decrease in active platelet 5-HT uptake while 
ECT treatment resulted in increase in active 
platelet 5-HT uptake 
The uptake of 5-HT in both brain and 
blood platelet requires active uptake process 
against a considerable concentration gradient 
(Blackburn etal., 1967; Chase etal., 1969) The 
process of passive uptake of 5-HT in both brain 
and blood platelets is of little or no physiologi-
cal importance, only contributing to uptake at 
high substrate concentrations and not influ-
enced by drugs such as imipramine which block 
the active transport process (Fusk et al., 1964) 
The 5-HT concentration in whole blood or plate-
lets and the total 5-HT uptake (both active & 
passive) lack the specificity which the active 
platelet 5-HT uptake has and do not parallel 
with the CNS parameters so closely as the ac-
tive platelet 5-HT uptake does. Hence, active 
platelet 5-HT uptake was studied and for this 
the estimation was done at a low concentration 
of 5-HT nnd for a short incubation period which 
is necessary for accurate results (Sneddon, 
1973). 
Active platelet 5-HT uptake was signifi-
cantly lower in depressed patients as compared 
to controls prior to treatment (table). Similar 
findings have been reported by Hallstrom et al. 
(1976), Scott et al. (1979), Ehsanullah (1980) 
and Born et al. (1980), However. Shaw et al. 
(1971) found no difference in the uptake of 
platelet 5-HT in depressed patients, but the 
excessive concentration of 5-HT and the long 
incubation time used in that study precluded 
accurate determination of active 5-HT 
Lingjaerde (1983) hypothesized that there 
is a lowered turnover of 5-HT in atleast a sub-
group of depressed patients which is reflected 
in lowered concentration of 5-HIAA in the CSF 
or lowered concentration of 5-HT in blood or in 
platelets or lowered active 5-HT uptake in blood 
platelets of these patients (uptake can be taken 
as a reflection for turnover). Moreover, as plate-
let can be taken as neuronal model for 5-HT, it 
can be interpreted that akin to platelets, in the 
pre-synaptic neurons the active 5-HT uptake is 
lowered in depressed patients which may be a 
compensatory mechanism, the function of 
which is to "make the best" out of the reduced 
amount of 5-HT in the synaptic cleft. 
Treatment with imipramine resulted in 
significant decrease in active platelet 5-HT 
uptake as compared to the pretreatment lev-
els It has been reported that patients receiving 
imipramine gradually loose upto 80% of the 
original 5-HT content of their platelets (Yates 
et al. 1963, Tuomisto, 1994) Todrick & Tait 
(1969) reported that tertiary amines were more 
potent inhibitors than their demethylated deriva-
tives to inhibit the uptake of 5-HT by human 
platelets. Several investigators have reported 
increase in Km but Vmax remaining same, i.e., 
the affinity of the transport is decreased, but 
the number of hypothetical molecules remains 
the same and concluded a purely competitive 
inhibition of imipramine on platelet 5-HT up-
take (Lingjaerde, 1979; Tuomisto et al., 1979; 
Meltzeretal., 1981). 
Tricyclic antidepressants exert their anti-
depressant action by the way of blockade of 
monoamine (5-HT or norepinephrine) uptake at 
presynaptic axoplasmic membrane (Kessel & 
Simpson, 1995; Rafaelsen, 1980; Lewis, 1974). 
The dimethylated tertiary amines (e.g. imi-
pramine and amitryptiline) are more potent in 
blocking serotonin uptake than the 
monomethylated secondary amines (e.g. 
desipramine and nortryptiline) which block 
norepinephrine more potently (Kessel & 
Simpson, 1995). 
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ECT successfully ameliorated the 
depressive symptoms. The mean duration of 
treatment with ECT was 3.99 weeks. The 
response rate was 82.77% which is in keeping 
with the reports that most of the depression 
show good therapeutic response to ECT 
(Dubovsky, 1995). 
As stated earlier that uptake could be 
taken as a reflection for turnover, the findings 
of the present study suggests that ECT might 
increase the turnover of 5-HT in platelets. 
Gayford et al. (1973) found increased 5-HT 
blood levels after ECT in depressed patients. 
Subramanyam (1975) reported that ECT pro-
duced sustained increase in synthesis, utiliza-
tion and turnover of the amines in the brain of 
depressives. Jori et al. (1975) reported that ECT 
determined significant increase in CSF 5-HIAA 
at the time of recovery than at the beginning of 
the treatment. Costain et al. (1979) found that 
ECT potentiates 5-HT effects in test animals 
(rats). Although no firm conclusions can be 
drawn, it is possible that by ECT increased 
turnover of 5-HT in blood platelets (findings of 
the present study), in blood (Gayford et al., 
1973) and increased turnover of CSF-5HIIA 
(Subramanyam, 1975; Jori et al., 1975; Costain 
et al., 1979) may be relevant to the 
antidepressant activity of ECT. 
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